Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display session

19P - Tumor retargeting universal chimeric antigen receptor T cell (TRUE-CAR T) therapy in solid tumors

Date

07 Mar 2022

Session

e-Poster Display session

Presenters

Fanyan Meng

Citation

Annals of Oncology (2022) 33 (suppl_1): S9-S12. 10.1016/annonc/annonc839

Authors

F. Meng1, Z. Sun2, B. Liu2

Author affiliations

  • 1 Affiliated Drum Tower Hospital Nanjing University, Nanjing/CN
  • 2 The Comprehensive Cancer Center of Drum Tower Hospital, Nanjing/CN
More

Abstract 19P

Background

The adoptive transfer of chimeric antigen receptor T cells (CAR-T cells) has demonstrated impressive clinical benefits in patients with hematological malignancies, however, no equivalent successes have been observed yet in solid tumors. The unsatisfactory outcome with solid tumors could be partly attributed to the lack of appropriate tumor-specific antigens. Here, we describe a novel strategy of tumor retargeting universal chimeric antigen receptor T cell therapy (TRUE-CAR T).

Methods

EGFRvIII antigenic peptide (EvIII) was conjugated with DSPE-PEG-Mal and was applied to construct fusogenic nanoparticles. Particle size, surface charge and stability of the nanoparticles were characterized. The antigen modification effect of EvIII-NP was evaluated through flow cytometry and confocal microscopy. In vivo anti-tumor effect and safety profile of TRUE-CAR-T were evaluated through tumor growth curve and tumor survival curve in subcutaneous and abdominal dissemination model of gastric cancer.

Results

MALDI-TOF-MS analysis demonstrated that EvIII antigenic peptide was successfully conjugated to DSPE-PEG-Mal. The particle size and surface charge of EvIII-NP was 113.1±1.24 nm and 11.2±0.12mV respectively. Flow cytometry and confocal image verified that EvIII-NP can modify tumor cells with antigen on their membrane. Near-infrared imaging indicated that the accumulation of intravenously transfusing EvIII-NPs in subcutaneous tumor reached its peak in 24 hours after administration. In vivo experiment demonstrated that the combination therapy of EvIII-NPs and EvIII CAR-T cells adoptive transfer effectively suppressed tumor growth and prolonged the life of experimental animals without obvious toxicity and side effects, in the subcutaneous and abdominal dissemination model of gastric cancer.

Conclusions

The TRUE-CAR T strategy possesses great clinical application potential with feasibility, universality and safety, providing new perspectives for CAR-T cells therapy in solid tumors.

Legal entity responsible for the study

Mouse studies were approved by the Laboratory Animal Care and Use Committee of the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

Funding

Grants from the National Natural Science Foundation of China (grant number 81930080, 82072926, 81572601), Natural Science Foundation of Jiangsu Province (grant number BK20191114), and Nanjing Medical Science and Technique Development Foundation (No. QRX17038).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.